How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine

British Journal of Cancer

Volumn 103, Issue 8, 2010, Pages 1139-1143

  Gerlinger, M ^a,b   Swanton, C ^a,c  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

drug resistance; evolution; genomic instability; heterogeneity

Indexed keywords

DASATINIB; GEFITINIB; IMATINIB; NILOTINIB; PLATINUM DERIVATIVE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT;

CANCER RESEARCH; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CLONE; CYTOTOXICITY; EVOLUTIONARY ADAPTATION; GENE MUTATION; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; GLIOBLASTOMA; LUNG NON SMALL CELL CANCER; OVARY CANCER; PRIORITY JOURNAL; RNA TRANSLATION; SHORT SURVEY; TREATMENT FAILURE; BIOLOGICAL MODEL; CELL CLONE; DRUG RESISTANCE; GENETICS; HUMAN; MOLECULAR EVOLUTION; NEOPLASMS; ONCOLOGY; REPRODUCTIVE FITNESS;

ANTINEOPLASTIC AGENTS; CLONE CELLS; DRUG RESISTANCE, NEOPLASM; EVOLUTION, MOLECULAR; GENETIC FITNESS; GENETIC HETEROGENEITY; HUMANS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; MODELS, GENETIC; NEOPLASMS; TREATMENT FAILURE;

EID: 77958014613     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605912     Document Type: Short Survey

References (37)

1. Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R, Goodhead I, Follows GA, Green AR, Futreal PA, Stratton MR (2008) Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci USA 105: 13081-13086
2. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38: 1043-1048
3. Druker BJ (2006) Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 354: 2594-2596
4. Duesberg P, Stindl R, Hehlmann R (2000) Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proc Natl Acad Sci USA 97: 14295-14300
5. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451: 1111-1115
6. Fialkow PJ (1979) Clonal origin of human tumors. Annu Rev Med 30: 135-143
7. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134
8. Fox EJ, Salk JJ, Loeb LA (2009) Cancer genome sequencing - an interim analysis. Cancer Res 69: 4948-4950
9. Gatenby RA, Silva AS, Gillies RJ, Frieden BR (2009) Adaptive therapy. Cancer Res 69: 4894-4903
10. Goldie JH, Coldman AJ (1984) The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 44: 3643-3653
11. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880
12. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58
13. Graves M (2000) Cancer: The Evolutionary Legacy. Oxford University Press: Oxford
14. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C, Edkins S, Bignell G, Davies H, O'Meara S, Parker A, Avis T, Barthorpe S, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Richardson D, Shepherd R, Small A, Solomon H, Tofts C, Varian J, West S, Widaa S, Yates A, Easton DF, Riggins G, Roy JE, Levine KK, Mueller W, Batchelor TT, Louis DN, Stratton MR, Futreal PA, Wooster R (2006) A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66: 3987-3991
15. Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, Suehisa H, Ouchida M, Aoe K, Aoe M, Kiura K, Shimizu N, Date H (2006) Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 66: 7854-7858
16. Klein CA (2006) Random mutations, selected mutations: a PIN opens the door to new genetic landscapes. Proc Natl Acad Sci USA 103: 18033-18034
17. Komarova NL, Wodarz D (2003) Evolutionary dynamics of mutator phenotypes in cancer: implications for chemotherapy. Cancer Res 63: 6635-6642
18. Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T (2006) Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12: 5764-5769
19. Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396: 643-649
20. Loeb LA (1991) Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51: 3075-3079
21. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139
22. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359: 366-377
23. Marusyk A, Polyak K (2010) Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 1805: 105-117
24. Merlo LM, Pepper JW, Reid BJ, Maley CC (2006) Cancer as an evolutionary and ecological process. Nat Rev Cancer 6: 924-935
25. Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA, Downing JR (2008) Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322: 1377-1380
26. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194: 23-28
27. Rahman N, Stratton MR (1998) The genetics of breast cancer susceptibility. Annu Rev Genet 32: 95-121
28. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, Fenaux P, Preudhomme C (2002) Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100: 1014-1018
29. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL (2002) Multiple BCR -ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125
30. Shojaei F, Ferrara N (2008) Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res 68: 5501-5504
31. Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, Komisopoulou E, Brown LM, Loo JA, Landaw EM, Sawyers CL, Graeber TG (2006) Phos-phorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci USA 103: 19466-19471
32. Sotillo R, Schvartzman JM, Socci ND, Benezra R (2010) Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature 464: 436-440
33. Swanton C (2009) Chromosomal instability determines taxane response. Proc Natl Acad Sci USA 106: 8671-8676
34. Tomlinson IP, Novelli MR, Bodmer WF (1996) The mutation rate and cancer. Proc Natl Acad Sci USA 93: 14800-14803
35. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW (2007) Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11: 25-36
36. Williams RT, den Besten W, Sherr CJ (2007) Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes Dev 21: 2283-2287
37. Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, Louis DN (2009) MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 15: 4622-4629